MedCore Peptides Contact →
MedCore Combination Research Profile

BPC-157 + TB-500 5 mg + 5 mg

A combined MedCore research presentation with BPC-157 5 mg and TB-500 5 mg, while preserving separate evidence boundaries for each peptide.

Review Evidence Model ↓Quality & Documentation →
MedCore BPC-157 and TB-500 5 mg plus 5 mg product presentation
MEDCORE PEPTIDESBPC-157 + TB-5005 mg + 5 mg research presentation
PresentationBPC-157 + TB-500
MedCore strength5 mg + 5 mg
BPC-157 CID9941957
TB-500 CID62707662
Evidence modelTwo separate compounds
Page reviewed2 Sep 2026

What is the BPC-157 + TB-500 combination?

This MedCore presentation contains two separately identifiable research peptides: BPC-157 and TB-500. PubChem lists BPC-157 as CID 9941957 and TB-500 as CID 62707662.12

A combination product does not create a new body of clinical evidence by itself. Public evidence for BPC-157 and TB-500 must be evaluated separately, and findings for either compound should not be assumed to establish the safety or efficacy of the combined MedCore presentation.

Evidence Boundaries for a Two-Compound Presentation

The most important scientific distinction is that a product-level combination should not merge two separate evidence bases into a single therapeutic claim.

Source separation

BPC-157 and TB-500 require independent evidence review

PubChem provides distinct standardized records for BPC-157 and TB-500. FDA likewise discusses the safety context of the two peptides separately. The source set used for this page does not establish product-specific clinical evidence for the MedCore 5 mg + 5 mg combination.123

What this establishesThe combined presentation can be documented as a product, while scientific statements remain traceable to the individual compounds.
BPC-157

Human evidence remains limited

The BPC-157 evidence layer is handled on its dedicated MedCore entity page and includes PubChem identity, the registered early-phase study and FDA safety context.

TB-500

FDA identifies major data gaps

FDA states that it has not identified human exposure data for drug products containing the TB-500 fragment and notes immunogenicity and impurity concerns.3

Evidence boundary

This page does not claim synergy, enhanced efficacy, validated dosing, clinical safety or therapeutic benefit from combining BPC-157 and TB-500. Any such claim would require direct evidence for the combination itself.

See authoritative sources →
MedCore BPC-157 plus TB-500 5 mg plus 5 mg research presentation

MedCore BPC-157 + TB-500 5 mg + 5 mg

The MedCore portfolio identifies this product as a 5 mg + 5 mg combination presentation. Product-level documentation should describe the actual MedCore batch and composition without borrowing unverified claims from external research.

Product nameBPC-157 + TB-500
BrandMedCore Peptides
Presentation strength5 mg + 5 mg
Portfolio groupPeptide combination
Website purposeResearch product information
Direct online checkoutNot available

Product-specific composition, batch and analytical information should be added only from verified MedCore documentation.

Quality & Product Documentation

The combined product can have one product-documentation layer while the scientific evidence remains compound-specific.

  • Two-compound product identification
  • Batch records when published
  • Analytical documents when verified
  • No inferred synergy claims
Explore the Quality Framework →
MC
MEDCORE PEPTIDESCombination profile
ProductBPC-157 + TB-500
Presentation5 mg + 5 mg
Identity sourcesPubChem ×2
Evidence modelCompound-specific
Safety contextFDA
Product-specific analytical documents can be connected when verified.

COA / Laboratory Documentation

Strength-specific documentation preview for the MedCore BPC-157 + TB-500 research presentation.

Sample COA / laboratory documentation for MedCore BPC-157 + TB-500 5 mg + 5 mg
BPC-157 + TB-500 5 mg + 5 mgSample documentation for presentation purposes; not independently verified.
Documentation note

These images are presented as sample product documentation and should not be interpreted as independently verified analytical certification. Product identity, batch data and analytical claims should be checked against original laboratory records.

Related MedCore Research Profiles

The individual compound pages remain the primary evidence hubs for each component.

Peptide researchBPC-157Explore profile →Peptide researchTB-500Explore profile →Peptide researchCJC-1295 DACExplore profile →

BPC-157 + TB-500 Questions & Answers

Product questions are answered without merging the compounds' separate evidence bases.

It is a combined MedCore research presentation containing BPC-157 5 mg and TB-500 5 mg.
No. Evidence about BPC-157 alone does not establish the safety or effect of a product that also contains TB-500.
No. TB-500 has its own evidence and safety context, which should be reviewed separately from BPC-157.
No. The source set used for this page does not establish product-specific clinical evidence for the MedCore combination.
No. MedCore uses the website as an informational portfolio and documentation platform.

Authoritative Sources

The combination page intentionally cites the two underlying compound records rather than manufacturing a single evidence narrative. Last reviewed 2 September 2026.

  1. 1
    PubChem: BPC-157

    Standardized compound identity for BPC-157.

    Open PubChem source ↗
  2. 2
    PubChem: TB-500, CID 62707662

    Standardized identity and sequence for TB-500.

    Open PubChem source ↗
  3. 3
    U.S. FDA: Certain Bulk Drug Substances That May Present Significant Safety Risks

    FDA safety context for BPC-157 and TB-500 in compounding.

    Open FDA source ↗
MEDCORE PEPTIDES

One combination product. Two evidence layers kept clearly separate.

Review the quality framework or the individual BPC-157 and TB-500 entity pages for source-separated context.

Quality & Documentation →Contact MedCore →
Research-use information: This page is informational and does not provide medical advice, dosing instructions, treatment recommendations, synergy claims or a representation that the combination is an approved medicine.
\n
Review the evidence contextUse the MedCore methodology and disclaimer when interpreting product research and documentation.
\n
\n\n